Anavex Life Sciences Corp.
8.02-0.08 (-0.99%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · AVXL · USD
Key Stats
Market Cap
688.87MP/E (TTM)
-Basic EPS (TTM)
-0.57Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Anavex Life Sciences posted a Q3 operating loss of $14.5M, edging up 0.1% y/y yet dipping 1.0% q/q (derived), driven by steady R&D outlays on blarcamesine trials amid wrapping up Alzheimer's extensions. Net loss widened to $13.2M or $0.16/share from $12.2M or $0.14/share y/y, with the gap tied to lower interest and R&D incentive income; YTD net loss hit $36.6M or $0.43/share versus $31.4M or $0.38/share, reconciling cleanly to 85.1M diluted shares. Cash burned $30.4M in operations YTD, leaving $101.2M on hand—enough runway past 12 months—bolstered by a fresh $150M sales pact post-quarter. No debt weighs in. Ongoing shareholder suits over Rett disclosures linger as a distraction.
8-K
ATM equity offering launched
Anavex Life Sciences entered a Sales Agreement on July 25, 2025, with TD Securities to offer up to $150 million in common stock via at-the-market sales on Nasdaq. The deal, under a freshly effective S-3 shelf registration, lets the biotech raise funds opportunistically without commitment. Commissions cap at 3% of proceeds. No sales yet.
8-K
Exec contract extensions announced
Anavex Life Sciences extended CEO Christopher Missling's employment through July 5, 2028, with a $800,000 base salary and 20% target bonus eligibility, while Principal Financial Officer Sandra Boenisch's agreement now runs indefinitely at $279,840 CAD annually, also with 20% bonus potential and doubled severance to 12 months. These amendments lock in leadership continuity amid clinical trials. No interim changes needed. Risks include performance-tied bonuses.
8-K
Incentive plan amended, shares increased
Anavex Life Sciences stockholders approved an amendment to the 2022 Omnibus Incentive Plan at the June 10, 2025 annual meeting, boosting authorized shares by 4 million to 14 million total. The changes impose a one-year minimum vesting for awards, with exceptions for change in control or death, while banning share recycling from tax withholdings or option exercises. This strengthens governance amid biotech talent competition. Yet dilution looms.
10-Q
Q2 FY2025 results
Anavex Life Sciences posted a Q2 FY2025 operating loss of $12.5M, edging down 0.9% y/y from $12.6M, while the six-month tally climbed 8.7% y/y to $26.1M amid ramped R&D on ANAVEX 3-71 schizophrenia trials and Alzheimer's MAA prep. Net loss widened to $11.2M ($0.13/share) from $10.5M y/y, driven by lower interest income and R&D incentives, yet EPS held steady against 3.2% more diluted shares (85.1M vs 82.5M). Cash burned $18.0M in operations over six months, leaving $115.8M on hand—enough runway past 12 months—bolstered by $1.6M option exercises; no debt weighs the balance sheet. Ongoing litigation shadows clinical disclosures. Cash fuels the pipeline.
AMLX
Amylyx Pharmaceuticals, Inc.
13.89-0.43
ANRO
Alto Neuroscience, Inc.
14.04+0.42
ANVS
Annovis Bio, Inc.
2.20+0.10
ATHE
Alterity Therapeutics Limited
4.70-0.06
ATXI
Avenue Therapeutics, Inc.
0.72+0.00
BLRX
BioLineRx Ltd.
3.50-0.18
NERV
Minerva Neurosciences, Inc
4.23-0.37
NRSN
NeuroSense Therapeutics Ltd.
1.06-0.06
NRXP
NRX Pharmaceuticals, Inc.
3.05+0.05
SAVA
Cassava Sciences, Inc.
3.42-0.16